As a result of the coronavirus disease 2019 (COVID-19) pandemic, radiation therapies have been modulated to reduce the risk of infection during outpatient activities and hypofractionated regimens or radiotherapy delay for nonmelanoma skin cancer (NMSC) were suggested. Hypofractionated radiotherapy not only may confer no disadvantage in regard to outcome when compared to a more protracted schedule but might also reduce the risk of infection. We report the experience of a dermatologic radiation therapy department concerning a group of patients with a diagnosis of NMSC selected for a radiation treatment plan aimed to minimize the number of their accesses to our department.
FilippiARRussiEMagriniSM, et al. Letter from Italy: first practical indications for radiation therapy departments during COVID-19 outbreak. Int J Radiat Oncol Biol Phys2020; 107: 597–599.
2.
RembielakASykesAJFifeK, et al. Radiotherapy and systemic treatment for non-melanoma skin cancer in the COVID-19 pandemic. Clin Oncol2020; 32: 417–419.
3.
VenessMJ.Hypofractionated radiotherapy in patients with non-melanoma skin cancer in the post COVID-19 era: time to reconsider its role for most patients. J Med Imaging Radiat Oncol2020; 64: 591–594.
4.
BaumannBCMacArthurKMBrewerJD, et al. Management of primary skin cancer during a pandemic: multidisciplinary recommendations. Cancer2020; 126: 3900–3906.
5.
GoldschmidtHPanizzonR.Therapy for cutaneous carcinoma. In: GoldschmidtHPanizzonR, eds. Modern Dermatologic Radiation Therapy. Springer-Verlag: 1991.
6.
GunaratneDAVenessMJ.Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: results of a systematic review. J Med Imaging Radiat Oncol2018; 62: 401–411.
7.
ZaorskyNGLeeCTZhangE, et al. Hypofractionated radiation therapy for basal and squamous cell skin cancer: a meta-analysis. Radiother Oncol2017; 125: 13–20.
8.
VenessM.Hypofractionated radiotherapy in older patients with non-melanoma skin cancer: less is better. Australas J Dermatol2018; 59: 124–127.
